Table 1.
Patient characteristics
| Characteristic | N (%) |
|---|---|
| Sample size | 85 |
| Median age at embolization (range) | 71 (50–87) |
| Sex | |
| Male | 68 (80) |
| Female | 17 (20) |
| Biopsy | |
| Positive for HCC | 68 (80) |
| Inconclusive | 3 (3.5) |
| No biopsy | 14 (16.5) |
| Cause of liver disease | |
| Hepatitis B/C | 35 (41.1) |
| Alcohol | 26 (30.6) |
| Hemochromatosis | 3 (3.5) |
| NASH | 6(7.1) |
| Alpha-1-antitrypsin | 1 (1.1) |
| Primary biliary cirrhosis | 1 (1.1) |
| Other/unknown | 14 (16.4) |
| Laboratory data | |
| AFP (median (range)) | 9 (2–47652) |
| Bilirubin (median (range)) | 1 (0–4) |
| Albumin (median (range)) | 4 (1–6) |
| INR (median (range)) | 1 (1–3) |
| Child Pugh score | |
| A | 50 (58.8) |
| B | 19 (22.4) |
| C | 16 (18.9) |
| ECOG | |
| 0 | 55 (64.7) |
| 1 | 30 (35.3) |
| BCLC stage | |
| A0 | 5 (5.9) |
| B1 | 39 (45.9) |
| C2 | 15 (17.6) |
| D3 | 26 (30.6) |
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; INR, international normalized ratio; NASH, nonalcoholic steatohepatitis